Search Results - "Hendrikx, Jeroen JMA"
-
1
Redispensing of expensive oral anticancer medicines: A practical application
Published in Journal of oncology pharmacy practice (01-04-2024)“…Introduction Increasing use of expensive oral anticancer medicines comes with the downside of a financial and environmental burden, partially caused by unused…”
Get full text
Journal Article -
2
Improving Appropriate Prescribing For Geriatric Patients Using a Clinical Decision Support System
Published in Innovations in pharmacy (14-04-2022)“…Purpose: Polypharmacy is a known risk factor for potentially inappropriate prescribing. Recently there is an increasing interest in clinical decision support…”
Get full text
Journal Article -
3
99mTcPSMA‐radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE‐II trial
Published in BJU international (01-07-2024)“…Objective To investigate whether combination treatment of prostate‐specific membrane antigen (PSMA)‐based radioguided surgery (RGS) with short‐term androgen…”
Get full text
Journal Article -
4
Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel
Published in International journal of cancer (01-01-2015)“…Organic anion transporting polypeptides (human: OATPs and mouse: Oatps) are uptake transporters with important roles in drug pharmacokinetics and toxicity. We…”
Get full text
Journal Article -
5
P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel
Published in International journal of cancer (15-05-2013)“…Paclitaxel is avidly transported by P‐glycoprotein (P‐gp/MDR1/ABCB1). This results in low oral bioavailability, which can be boosted by coadministration of…”
Get full text
Journal Article -
6
A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir
Published in European journal of cancer (1990) (01-11-2017)“…Two solid dispersions of docetaxel (denoted ModraDoc001 capsule and ModraDoc006 tablet (both 10 mg)) were co-administered with 100 mg ritonavir (/r) and…”
Get full text
Journal Article -
7
Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model
Published in International journal of cancer (01-02-2016)“…Docetaxel (Taxotere®) is currently used intravenously as an anticancer agent and is primarily metabolized by Cytochrome P450 3A (CYP3A). The HIV protease…”
Get full text
Journal Article -
8
Genetically modified mouse models for oral drug absorption and disposition
Published in Current opinion in pharmacology (01-12-2013)“…Highlights • Intestinal drug absorption can be limited by Mrp2, P-gp and Bcrp. • Octn1 and Octn2 may facilitate intestinal drug absorption. • Enterocyte…”
Get full text
Journal Article -
9
P‑glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice
Published in Molecular pharmaceutics (05-10-2015)“…We aimed to clarify the roles of the multidrug-detoxifying proteins ABCB1, ABCG2, ABCC2, and CYP3A in oral availability and brain accumulation of cabazitaxel,…”
Get full text
Journal Article -
10
A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry
Published in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (15-10-2011)“…► A validated LC–MS/MS method is described for the simultaneously quantification of paclitaxel, docetaxel and ritonavir. ► Drugs with diverse individual…”
Get full text
Journal Article -
11
A Phase 1 Dose‐Escalation Study of Low‐Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors
Published in Clinical pharmacology in drug development (01-06-2021)“…ModraPac001 (MP1) and ModraPac005 (MP5) are novel oral paclitaxel formulations that are coadministered with the cytochrome P450 3A4 inhibitor ritonavir (r),…”
Get full text
Journal Article -
12
Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
Published in Clinical pharmacology: advances and applications (01-01-2020)“…Jeroen JMA Hendrikx,1- 3 Jos H Beijnen,1 Alwin DR Huitema1- 3 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The…”
Get full text
Journal Article